Chinese factory's Retatrutide high-quality peptide products, which are beneficial for regulating blood sugar and energy metabolism. The products come
TDS 2 Inquiries
2406696-90-8
Pharmaceutical Grade
99%
hongkong
Customized services available
10mg 20mg
2026-08-31
Retatrutide,Tirzepatide,GLOW,KLOW80,NAD+,TB500
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
NA
CAS No.:2406696-90-8
Molecular Formula:C15H18F3N3O3
Molecular Weight:345.32
Categories:
Characteristics-
Density:
1.407±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:549.890±50.00 °C(Press: 760.00 Torr)(predicted)
PKA:9.132±0.10(predicted)
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,GLOW,KLOW80,NAD+,TB500
-
Location:
Room 11B, Building 0056, No. 81-1 Nonglinxia Road, Yuexiu District, Guangzhou City, Guangdong Province
-
Payment Terms:
100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
United States
Survodutide
5 Mar 3, 2026
United States
Survodutide
2 MT Feb 15, 2026 Post an enquiry for this product